A unit of Jardine Matheson Group is considering selling its car dealership in Malaysia and Singapore, people familiar with the matter said. Singapore-listed Jardine Cycle & Carriage Ltd. is working with an adviser on a possible sale of the dealership and has reached out to potential buyers, the people said, asking not to be identified because the information is private. A transaction could value t...
A unit of Jardine Matheson Group is considering selling its car dealership in Malaysia and Singapore, people familiar with the matter said. Singapore-listed Jardine Cycle & Carriage Ltd. is working with an adviser on a possible sale of the dealership and has reached out to potential buyers, the people said, asking not to be identified because the information is private. A transaction could value the business at $250 million to $350 million, they said. Deliberations are ongoing and might not result in a sale, the people said. A representative for Jardine Cycle & Carriage declined to comment. Jardine Matheson holds about 85% of Jardine Cycle & Carriage, owner of the dealership , which retails and provides aftersales services for new and used vehicles in Malaysia and Singapore. Brands offered include Mercedes-Benz, Mitsubishi, Kia, Citroen and Peugeot, its website shows . Jardine Cycle & Carriage shares have climbed about 27% in the past 12 months, giving the holding company a market value of S$12.8 billion ($10.1 billion). Its other investments in the region include Indonesian conglomerate PT Astra International and automotive dealership Tunas Ridean, as well as Vietnam’s Truong Hai Group Corp., or Thaco, and Refrigeration Electrical Engineering Corp.
Earnings Call Insights: Monster Beverage (MNST) Q1 2026 Management View “We’re pleased to report another quarter of strong financial results and cash generation with net sales crossing the $2 billion threshold for the first time in the company’s history for a fiscal first quarter,” said CEO & Vice Chairman Hilton Schlosberg, while adding that “sales increased by double digits compared to the prior...
Earnings Call Insights: Monster Beverage (MNST) Q1 2026 Management View “We’re pleased to report another quarter of strong financial results and cash generation with net sales crossing the $2 billion threshold for the first time in the company’s history for a fiscal first quarter,” said CEO & Vice Chairman Hilton Schlosberg, while adding that “sales increased by double digits compared to the prior year in all geographic regions” and that Monster “gained share in many of our global markets in the first quarter.” Schlosberg said tariffs and aluminum were “modest” in Q1 but framed a sequential cost headwind: “based on current aluminum pricing in the Midwest premium, we expect a continued modest sequential increase in our costs through at least the end of 2026 as compared to the 2026 first quarter,” and added, “we will continue to recognize tariffs on aluminum due to the higher Midwest premium and continue to implement hedging strategies across the business where possible.” CFO remarks were not included in the provided transcript beyond CEO-prepared financial commentary (Tom Kelly was introduced, but no CFO statement was transcribed). CEO of the Americas Rob Gehring tied pricing to category resilience: “we continue to evaluate our financials, the consumer, the ability and the resiliency of the category and how it stands up under pricing,” and “thus far, we’re very pleased with the pricing actions we took in late 2025.” CEO of EMEA & OSP Guy Carling pointed to continued share gains alongside pricing discipline: “modest inflationary pricing is working. The category is healthy, and we’re gaining share in the category.” Outlook The company did not issue formal quarterly or annual EPS/revenue guidance in this transcript; management reiterated a cost and pricing posture rather than numeric targets. Schlosberg reiterated pricing optionality and cost inflation monitoring: “we continue to review opportunities for price increases, both domestically and internationally,” while des...
Earnings Call Insights: Ginkgo Bioworks (DNA) Q1 2026 Management View "In 2026, our focus will be on investing to win the category of autonomous labs" (CEO Jason Kelly), adding that Ginkgo’s two main actions are "to take our services...and run them on top of our autonomous lab here in Boston that we call Nebula" and "getting early adopters of autonomous labs out in the world to buy our systems." "...
Earnings Call Insights: Ginkgo Bioworks (DNA) Q1 2026 Management View "In 2026, our focus will be on investing to win the category of autonomous labs" (CEO Jason Kelly), adding that Ginkgo’s two main actions are "to take our services...and run them on top of our autonomous lab here in Boston that we call Nebula" and "getting early adopters of autonomous labs out in the world to buy our systems." "We were able to close...the spin-off of our biosecurity unit into a new company called Perimeter" (CEO Kelly), describing "$60 million" raised for Perimeter and saying "Ginkgo is a shareholder in that company" and "this is really nice...opportunity...for Ginkgo to keep our focus on the autonomous labs." "We have and will retrospectively recast all prior periods presented to conform to this presentation" (CFO Steven Coen) as biosecurity is now treated as discontinued operations; Coen said, "Following the biosecurity divestiture, we now operate as a single segment" and "all of the financial commentary I will provide today relates exclusively to continuing operations." "We have some news this month in terms of expanding" Nebula (CEO Kelly), including that Ginkgo is "at 50-plus right now" and "103 racks will be coming online just in about a week," and he highlighted proof-points including "over 100 protocols with more than 30 of them being unique" and "on a peak day on Nebula, we had 439 or so scientists submitting." Outlook "We are reaffirming our overall cash burn guidance for 2026, totaling $125 million to $150 million" (CFO Coen), saying the range reflects "a firm balance amongst cost efficiency, continuing services and tools and further investments we are making" in autonomous labs. "We have turned the page on our pure focus on restructuring actions" (CFO Coen), and framed 2026 as "continuing to be cost efficient, while investing in our AI robotics and software to bring autonomous labs to our bioscience customers, including the build-out of our Frontier Autonomous Lab in B...
Earnings Call Insights: Vericel Corporation (VCEL) Q1 2026 Management View "The company generated record first quarter total revenue of more than $68 million, which increased 30% over last year and significantly exceeded our guidance for the quarter" (CEO, President & Director Dominick C. Colangelo), adding that this performance supported "significant margin expansion and profit growth" and "more ...
Earnings Call Insights: Vericel Corporation (VCEL) Q1 2026 Management View "The company generated record first quarter total revenue of more than $68 million, which increased 30% over last year and significantly exceeded our guidance for the quarter" (CEO, President & Director Dominick C. Colangelo), adding that this performance supported "significant margin expansion and profit growth" and "more than $15 million of free cash flow." "Based on our first quarter outperformance... and the NexoBrid BARDA procurement revenue expected in the second half of the year, we're raising our total revenue guidance range by $10 million for the full year" (CEO Colangelo). "We achieved an important milestone for the company with the FDA approval for MACI commercial manufacturing at our new facility, which began in the second quarter" (CEO Colangelo), saying the approval "increases our manufacturing capacity" and "enables the potential commercialization of MACI outside the United States." "We also announced a BARDA award valued at up to $197 million for the procurement and advanced development of NexoBrid" (CEO Colangelo), specifying "the base period contract of $35 million includes approximately $10 million over the next 12 months for the initial procurement of NexoBrid" and includes optional awards over "the 10-year period." "Total revenue increased 30% to $68.4 million" (CFO & Treasurer Joseph Mara), who highlighted that "MACI's momentum continued" and that the company ended the quarter with "approximately $211 million in cash and investments." Outlook "We now expect total revenue of $326 million to $336 million for the year" (CFO Mara), and said the company "continue[s] to expect gross margin of approximately 75% and adjusted EBITDA margin of approximately 27%." "We are raising full year MACI revenue guidance to $282 million to $288 million compared to the prior guidance of $280 million to $286 million" (CFO Mara), and added, "we expect approximately $62.5 million to $63.5 millio...
Earnings Call Insights: NuScale Power (SMR) Q1 2026 Management View CEO John Hopkins framed the quarter around NuScale’s licensing position and deployment readiness, saying NuScale is “the only SMR company in the world to have earned U.S. Nuclear Regulatory Commission standard design approval” and adding, “we've done it for 2 separate designs, our 50-megawatt and our 77-megawatt modules.” Hopkins ...
Earnings Call Insights: NuScale Power (SMR) Q1 2026 Management View CEO John Hopkins framed the quarter around NuScale’s licensing position and deployment readiness, saying NuScale is “the only SMR company in the world to have earned U.S. Nuclear Regulatory Commission standard design approval” and adding, “we've done it for 2 separate designs, our 50-megawatt and our 77-megawatt modules.” Hopkins highlighted project activity despite “a quieter quarter from an announcement perspective,” citing “continued advancement on the ENTRA1 and TVA power purchase agreement discussions,” RoPower progress in Romania after “Nuclearelectrica shareholders voted to advance the project,” and supply chain engagement with “our fuel supplier Framatome and manufacturing partner, Doosan Enerbility.” Hopkins emphasized siting flexibility tied to behind-the-meter approval and emergency planning, stating, “We are the only nuclear technology approved by the U.S. Nuclear Regulatory Commission for behind-the-meter operations paired with a groundbreaking emergency planning zone ... that limits the EPZ to the plant's own site boundary.” CFO Robert Hamady described liquidity and the quarter’s revenue dynamics: “NuScale's overall liquidity stood at $1 billion at March 31, 2026, an increase to over $1.2 billion by early May of 2026.” Outlook Management did not provide formal revenue or EPS guidance in the prepared remarks; commentary focused on timing and commercialization milestones around TVA/ENTRA1. CFO Hamady set an execution ambition tied to cash flow: “We anticipate, we expect -- we believe we won't be talking in terms of burn rate by the end of this year. I hope to be operationally cash flow positive by the end of this year.” On TVA timing, Hamady said, “We're hopeful that TVA can come across the line at some point later this year,” and linked a PPA to early services work: “so TVA come across line with, for example, PPA, we anticipate that we will have site-specific -- site-specific services, ...
Earnings Call Insights: Diodes Incorporated (DIOD) Q1 2026 Management View "first quarter revenue grew 22% year-over-year and above seasonal 3.5% sequentially" (President, CEO & Director Gary Yu), adding that the quarter reflected "solid demand recovery" and "momentum we are seeing across our key focus areas of automotive, industrial and AI server-related applications." "gross margin improved 70 b...
Earnings Call Insights: Diodes Incorporated (DIOD) Q1 2026 Management View "first quarter revenue grew 22% year-over-year and above seasonal 3.5% sequentially" (President, CEO & Director Gary Yu), adding that the quarter reflected "solid demand recovery" and "momentum we are seeing across our key focus areas of automotive, industrial and AI server-related applications." "gross margin improved 70 basis points sequentially" (President, CEO & Director Yu), attributing it "mainly to the higher revenue contribution from automotive and industrial markets" and "improving utilization," and noting, "automotive and industrial markets... totaled 44% of product revenue." "we delivered an over 100% year-over-year increase in quarterly earnings" (President, CEO & Director Yu), while reiterating the company’s interim targets: "reaching $2 billion in annual revenue, $700 million in gross profit and over $4 in non-GAAP EPS." "Revenue for the first quarter 2026 was $405.5 million" (Chief Financial Officer Brett Whitmire), and "GAAP net income for the first quarter was $15 million or $0.32 per diluted share" while "Non-GAAP adjusted net income in the first quarter was $19.8 million or $0.43 per diluted share." "our channel inventory decreased again this quarter, both in dollars and in weeks" (Senior Vice President of Worldwide Sales & Marketing Emily Yang), and "our global POS increased sequentially," while also stating, "we also continue to benefit from the market supply disruption" and "remain strategically selective and focused on long-term sustainable business and demand creation." Outlook "for the second quarter, we expect revenue to be approximately $435 million, plus or minus 3%" (Chief Financial Officer Whitmire), alongside "GAAP gross margin... 32.8%, plus or minus 1%" and "Non-GAAP adjusted EPS... $0.60, plus or minus $0.10." "we have refined the presentation of our guidance to help simplify the information provided, while also aligning to the 3-year financial targets we've ...
Earnings Call Insights: Delcath Systems (DCTH) Q1 2026 Management View CEO Gerard Michel said the quarter was “marked by 4-centre activations and record new patient starts in the first quarter,” and he positioned site activations, utilization, and referral networks as “core growth drivers for the business.” CEO Michel reported, “As of today, we have 29 REMS-certified sites, and we are in active di...
Earnings Call Insights: Delcath Systems (DCTH) Q1 2026 Management View CEO Gerard Michel said the quarter was “marked by 4-centre activations and record new patient starts in the first quarter,” and he positioned site activations, utilization, and referral networks as “core growth drivers for the business.” CEO Michel reported, “As of today, we have 29 REMS-certified sites, and we are in active discussions with over 50 potential new centers,” adding that “38 of these centers have had one or more members of a potential treatment team take the time to travel and be preceptive.” CEO Michel updated site expectations: “We are modifying our year-end activated center build to 37 active centers with 40 active center treatment centers sometime in the first quarter of 2027,” while reiterating, “it is very difficult to predict pacing.” CEO Michel tied utilization to CHOPIN, stating, “the publication of the CHOPIN results in Lancet Oncology is already changing treatment patterns at certain centers,” and he cited CHOPIN metrics: “response rates improved from approximately 40% with HEPZATO alone to about 76% when HEPZATO was combined with immunotherapy,” with “a clear separation between survival curves of both 1 and 2 years.” CFO Sandra Pennell reported, “Total revenue in the first quarter of 2026 was $25 million,” and added, “We ended the quarter with $89.3 million in cash and investments and no debt,” alongside capital return: “We also purchased approximately 300,000 common shares for about $3 million in the first quarter under the company's approved $25 million share buyback program.” Outlook CFO Pennell reaffirmed 2026 guidance and profitability expectations: “We are confident we will achieve total revenue of at least $100 million, which reflects 20% growth in HEPZATO kit volume over 2025,” and “we now expect to report positive adjusted EBITDA for the remainder of the year.” CFO Pennell maintained margin expectations: “Forecast for 2026 gross margins remain between 85% to 87%...
Court Strikes Down Trump's Replacement Tariffs; A Minor, Temporary Setback, With Sec 301 Tariffs Coming After the close on Thursday, the Court of International Trade (CIT) ruled to invalidate Trump's latest set of universal 10% tariff imposed two months ago under Sec. 122. The administration will quickly appeal this decision before it takes effect May 12. If the case follows the same pattern as th...
Court Strikes Down Trump's Replacement Tariffs; A Minor, Temporary Setback, With Sec 301 Tariffs Coming After the close on Thursday, the Court of International Trade (CIT) ruled to invalidate Trump's latest set of universal 10% tariff imposed two months ago under Sec. 122. The administration will quickly appeal this decision before it takes effect May 12. If the case follows the same pattern as the challenge to the IEEPA tariffs last year, a higher court might soon stay this ruling and leave the tariffs in place pending a longer review. As the tariffs are due to expire July 24, even if the Supreme Court (SCOTUS) eventually rules against these tariffs, there is a good chance a full judicial review will take long enough that the tariffs will remain in effect until the administration replaces them with new tariffs under Sec. 301 (unfair trade practices) and Sec. 232 (national security). As a reminder, Section 122 tariffs were always a stopgap: by statute, they can only be in place for 150 days, so they’ll expire on July 24, 2026. Investigations by the US Trade Representative under Section 301 are widely expected to wrap up before then, clearing the way for permanent replacement tariffs. That said, if the ruling survives appeal, the government will likely have to refund unlawfully collected duties, adding to the nearly $170 billion already owed as a result of the Feb. 20 decision. Key Points: 1. The CIT ruling was a split decision, with two Democratic-appointed judges granting summary judgment against the administration’s position and one Republican-appointed judge dissenting, favoring a full review of the case instead. This is in contrast to the CIT’s earlier ruling last year, in which a panel of one Democratic- and two Republican-appointed judges unanimously granted summary judgment against the IEEPA tariffs. 2. The CIT ruling gives the administration 5 days to rescind the tariffs, and requires that importers be paid refunds plus interest. We expect the administration...
After a rough start to 2026, shares of AI (artificial intelligence) chipmaker Nvidia (NASDAQ: NVDA) have come roaring back. The stock has soared about 19% over the last 30 days, and at one point in late April completed more than a 32% rally off a late-March low. With the stock trading close to $212 as of this writing, they're just shy of their April 27 all-time closing high of $216.61. That kind o...
After a rough start to 2026, shares of AI (artificial intelligence) chipmaker Nvidia (NASDAQ: NVDA) have come roaring back. The stock has soared about 19% over the last 30 days, and at one point in late April completed more than a 32% rally off a late-March low. With the stock trading close to $212 as of this writing, they're just shy of their April 27 all-time closing high of $216.61. That kind of run might give some investors pause, especially heading into the company's fiscal first-quarter results on May 20. Has the easy money already been made? Or could shares keep climbing as the AI build-out rolls on? The answer comes down to how durable hyperscaler spending really is, and whether Nvidia's pricing power can hold up as more customers begin developing their own chips. Image source: Getty Images. Continue reading